The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
A randomized, pilot trial of etanercept in dermatomyositis
Open accessAbstract
Objective: The aims of this pilot study were to assess (1) the safety and tolerability of etanercept in dermatomyositis (DM); (2) the feasibility and safety of a forced prednisone taper; and (3) outcome measures, including those recommended by the International Myositis Assessment Clinical Study (IMACS) group. Methods: We conducted a randomized, double‐blind, placebo‐controlled trial of etanercept (50mg subcutaneously weekly) for 52 weeks in DM subjects. Subjects were tapered off prednisone in a standardized schedule as tolerated over the initial 24 weeks of the study. Principal outcomes included adverse events, time from randomization to treatment failure (inability to wean off prednisone on schedule), and average prednisone dosage after week 24. Results: Sixteen subjects were randomized, 11 to etanercept and 5 to placebo. There were no significant differences in adverse event rates between the treatment groups, although 5 etanercept‐treated and 1 placebo‐treated subjects developed worsening rash. All 5 subjects receiving placebo were treatment failures (median time to treatment failure 148 days). In contrast, 5 of 11 subjects in the etanercept arm were successfully weaned off prednisone; the median time to treatment failure in this group was 358 days ( p = 0.0002). The median of the average prednisone dosage after week 24 was 29.2mg/day in the placebo group and 1.2mg/day in the etanercept group ( p = 0.02). IMACS and other outcome measures demonstrated excellent test–retest reliability (intraclass correlation coefficients 0.79–0.99). There was no significant treatment effect on functional outcome. Interpretation: The findings of no major safety concerns and a steroid‐sparing effect in our study suggest that further investigation of etanercept as a treatment for DM is warranted. Ann Neurol 2011;
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Statistical Analysis with Missing Data
Little, R. J. A., & Rubin, D. B. (2002) · Wiley Series in Probability and Statistics · doi:10.1002/9781119013563 · Cited by 8,473
Effect Sizes for Interpreting Changes in Health Status
Kazis, L. E., Anderson, J. J., & Meenan, R. F. (1989) · Medical Care · doi:10.1097/00005650-198903001-00015 · Cited by 2,401
Cited by
Idiopathic inflammatory myopathies
Lundberg, I. E., Fujimoto, M., Vencovsky, J., Aggarwal, R., Holmqvist, M., Christopher-Stine, L., Mammen, A. L., & Miller, F. W. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00321-x · Cited by 703
Classification and management of adult inflammatory myopathies
Selva-O'Callaghan, A., Pinal-Fernandez, I., Trallero-Araguás, E., Milisenda, J. C., Grau-Junyent, J. M., & Mammen, A. L. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30254-0 · Cited by 430
Current Classification and Management of Inflammatory Myopathies
Schmidt, J. (2018) · Journal of Neuromuscular Diseases · doi:10.3233/jnd-180308 · Cited by 324
Aggarwal, R., Bandos, A., Reed, A. M., Ascherman, D. P., Barohn, R. J., Feldman, B. M., Miller, F. W., Rider, L. G., Harris‐Love, M. O., Levesque, M. C., et al. (2014) · Arthritis & Rheumatology · doi:10.1002/art.38270 · Cited by 281
Self-citationAn overview of polymyositis and dermatomyositis
Findlay, A. R., Goyal, N. A., & Mozaffar, T. (2015) · Muscle & Nerve · doi:10.1002/mus.24566 · Cited by 259
Metadata
- Authors
- The Muscle Study Group
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2011-06-17
- Volume
- 70
- Issue
- 3
- Pages
- 427-436
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W4236000211
- Cited by
- 167
- References
- 2
- FWCI
- 12.10
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A randomized, pilot trial of etanercept in dermatomyositis. https://app.cochat.ai/papers/10.1002/ana.22477
- The paper
- The Muscle Study Group. (2011). A randomized, pilot trial of etanercept in dermatomyositis. Annals of Neurology. https://doi.org/10.1002/ana.22477
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.